$RNA News

Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25

Atrium Therapeutics Reports First Quarter 2026 Financial Results

Atrium Therapeutics Q1 EPS $(0.97) Beats $(1.10) Estimate, Sales $19.635M Beat $2.000M Estimate

HC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline

Novartis acquisition spin-off pioneers RNA therapeutics for the heart

Wells Fargo Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

Atrium Therapeutics Launches As A Newly-Independent Company Focusing On RNA Therapeutics

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences Announces Expected Record Date for Spin-Off